DEFINIUM THERAPEUTICS INC (DFTX) — insider trading
Health Care · NASDAQ
DEFINIUM THERAPEUTICS INC (DFTX) has 43 reported SEC Form 4 insider transactions in our data, including 11 open-market sales among the most recent 43 (latest 2026-09-25).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-25 | Karlin Daniel | Director, Officer (Chief Medical Officer) | Open-market sale | 10,853 | $36.57 | $396.9K | Form 4 |
| 2026-09-25 | Wiley Matthew T. | Officer (Chief Commercial Officer) | Open-market sale | 3,097 | $36.57 | $113.3K | Form 4 |
| 2026-09-25 | Sullivan Mark | Officer (Chief Legal Officer) | Open-market sale | 14,051 | $36.57 | $513.8K | Form 4 |
| 2026-09-25 | Roberts Brandi | Officer (Chief Financial Officer) | Open-market sale | 3,377 | $36.57 | $123.5K | Form 4 |
| 2026-09-25 | Barrow Robert | Director, Officer (Chief Executive Officer) | Open-market sale | 31,550 | $36.57 | $1.15M | Form 4 |
| 2026-09-18 | Krebs Andreas | Director | Option exercise / conversion (derivative) | 1,629 | — | $0 | Form 4 |
| 2026-09-18 | Krebs Andreas | Director | Option exercise / conversion | 1,629 | $35.52 | $57.9K | Form 4 |
| 2026-09-18 | Vallone Carol A | Director | Option exercise / conversion (derivative) | 1,086 | — | $0 | Form 4 |
| 2026-09-18 | Vallone Carol A | Director | Option exercise / conversion | 1,086 | $35.52 | $38.6K | Form 4 |
| 2026-09-14 | Karlin Daniel | Officer (Chief Medical Officer) | Grant / award / vesting | 200,000 | — | $0 | Form 4 |
| 2026-09-14 | Wiley Matthew T. | Officer (Chief Commercial Officer) | Grant / award / vesting | 125,000 | — | $0 | Form 4 |
| 2026-09-14 | Sullivan Mark | Officer (Chief Legal Officer) | Grant / award / vesting | 125,000 | — | $0 | Form 4 |
| 2026-09-14 | Roberts Brandi | Officer (Chief Financial Officer) | Grant / award / vesting | 125,000 | — | $0 | Form 4 |
| 2026-09-14 | Barrow Robert | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 750,000 | — | $0 | Form 4 |
| 2026-09-03 | Barrow Robert | Director, Officer (Chief Executive Officer) | Open-market sale | 19,023 | $37.94 | $721.7K | Form 4 |
| 2026-09-02 | Barrow Robert | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 40,000 | — | $0 | Form 4 |
| 2026-08-12 | Roberts Brandi | Officer (Chief Financial Officer) | Grant / award / vesting | 62,500 | — | $0 | Form 4 |
| 2026-08-12 | Wiley Matthew T. | Officer (Chief Commercial Officer) | Grant / award / vesting | 62,500 | — | $0 | Form 4 |
| 2026-08-12 | Sullivan Mark | Officer (Chief Legal Officer) | Grant / award / vesting | 62,500 | — | $0 | Form 4 |
| 2026-08-12 | Karlin Daniel | Officer (Chief Medical Officer) | Grant / award / vesting | 100,000 | — | $0 | Form 4 |
| 2026-08-12 | Barrow Robert | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 375,000 | — | $0 | Form 4 |
| 2026-06-25 | Wiley Matthew T. | Officer (Chief Commercial Officer) | Open-market sale | 2,867 | $45.03 | $129.1K | Form 4 |
| 2026-06-25 | Karlin Daniel | Officer (Chief Medical Officer) | Open-market sale | 10,035 | $45.03 | $451.9K | Form 4 |
| 2026-06-25 | Barrow Robert | Director, Officer (Chief Executive Officer) | Open-market sale | 29,208 | $45.03 | $1.32M | Form 4 |
| 2026-06-25 | Roberts Brandi | Officer (Chief Financial Officer) | Open-market sale | 3,013 | $45.03 | $135.7K | Form 4 |
| 2026-06-25 | Sullivan Mark | Officer (Chief Legal Officer) | Open-market sale | 13,008 | $45.03 | $585.8K | Form 4 |
| 2026-06-22 | Karlin Daniel | Officer (Chief Medical Officer) | Grant / award / vesting | 100,000 | — | $0 | Form 4 |
| 2026-06-22 | Sullivan Mark | Officer (Chief Legal Officer) | Grant / award / vesting | 62,500 | — | $0 | Form 4 |
| 2026-06-22 | Roberts Brandi | Officer (Chief Financial Officer) | Grant / award / vesting | 62,500 | — | $0 | Form 4 |
| 2026-06-22 | Barrow Robert | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 375,000 | — | $0 | Form 4 |
| 2026-06-22 | Wiley Matthew T. | Officer (Chief Commercial Officer) | Grant / award / vesting | 62,500 | — | $0 | Form 4 |
| 2026-06-11 | Bruhn Suzanne Louise | Director | Grant / award / vesting (derivative) | 19,188 | — | $0 | Form 4 |
| 2026-06-11 | Bruhn Suzanne Louise | Director | Grant / award / vesting | 4,666 | — | $0 | Form 4 |
| 2026-06-11 | Adsett Roger | Director | Grant / award / vesting (derivative) | 14,620 | — | $0 | Form 4 |
| 2026-06-11 | Adsett Roger | Director | Grant / award / vesting | 3,555 | — | $0 | Form 4 |
| 2026-06-11 | Krebs Andreas | Director | Grant / award / vesting (derivative) | 19,188 | — | $0 | Form 4 |
| 2026-06-11 | Krebs Andreas | Director | Grant / award / vesting | 4,666 | — | $0 | Form 4 |
| 2026-06-11 | Vallone Carol A | Director | Grant / award / vesting (derivative) | 19,188 | — | $0 | Form 4 |
| 2026-06-11 | Vallone Carol A | Director | Grant / award / vesting | 4,666 | — | $0 | Form 4 |
| 2026-06-11 | GRYSKA DAVID W | Director | Grant / award / vesting (derivative) | 19,188 | — | $0 | Form 4 |
| 2026-06-11 | GRYSKA DAVID W | Director | Grant / award / vesting | 4,666 | — | $0 | Form 4 |
| 2026-06-11 | CRYSTAL ROGER | Director | Grant / award / vesting (derivative) | 19,188 | — | $0 | Form 4 |
| 2026-06-11 | CRYSTAL ROGER | Director | Grant / award / vesting | 4,666 | — | $0 | Form 4 |
Ask the chat about DFTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: DEFINIUM THERAPEUTICS INC (DFTX).
Last updated 2026-09-25 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.